The Biosimilars Council works to ensure a positive regulatory, reimbursement, political and policy environment for biosimilar products, and will educate the public and patients about the safety and effectiveness of biosimilars. Areas of focus will include education, access, the nascent regulatory environment, reimbursement and legal affairs. Member organizations include any company or stakeholder organization working to develop biosimilar products with the intent to compete in the U.S. market.
The Biosimilars Council is a division of the Association for Accessible Medicines (formerly GPhA), an organization dedicated to improving access to safe, quality, effective medicine. To learn more, visit www.accessiblemeds.org.
Please email email@example.com for more information.
“Biosimilars hold the key to ensuring affordable access to biologic-alternatives medicines for all consumers. We exist to educate, advocate, and promote the development of these products.”
– Biosimilars Council Executive Director,
Christine Simmon, Executive Director
AAM Senior Vice President, Policy & Strategic Alliances
Christine Simmon joined the Association for Accessible Medicines (formerly GPhA) in 2012 as the Senior Vice President of Policy & Strategic Alliances, and most recently was named Executive Director of AAM’s Biosimilars Council, founded in 2015.
In her current role, Christine is responsible for leading policy development and issues management for AAM, directing the Biosimilars Council, and building relationships with strategic partners in the health care sector, including patient advocacy groups.
Joseph Stewart, Senior Manager
Joseph Stewart is the Senior Manager for the The Biosimilars Council, a division of the Association of Accessible Medicines (formerly known as the Generic Pharmaceutical Association (GPhA), which works to support the broad components of the biosimilar industry, and enable patients increased access to safe, effective and affordable biosimilar medicines.
Previously, Joseph worked as a federal government relations consultant at a boutique lobbying firm on Capitol Hill, whose portfolio of clients included voluntary health agencies, physician societies, pharmaceutical companies, specialty pharmacies, and health profession schools.